Pictet Asset Management (Switzerland)’s CRISPR Therapeutics CRSP Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$487K	Hold	8,674	–	–	﹤0.01%	1255
2023 Q1	$392K	Hold	8,674	–	–	﹤0.01%	1362
2022 Q4	$353K	Sell	8,674 -27,633	-76%	-$1.47M	﹤0.01%	1409
2022 Q3	$2.37M	Sell	36,307 -386,980	-91%	-$28M	﹤0.01%	897
2022 Q2	$25.7M	Buy	423,287 +419,387	+10,754%	+$24.7M	0.04%	404
2022 Q1	$245K	Hold	3,900	–	–	﹤0.01%	1459
2021 Q4	$296K	Hold	3,900	–	–	﹤0.01%	1401
2021 Q3	$437K	Buy	+3,900	New	+$490K	﹤0.01%	1252

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CRSP Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) held its CRISPR Therapeutics (CRSP) position steady in Q2 2023 at 8,674 shares worth $487K. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Pictet Asset Management (Switzerland) first reported a position in CRSP in Q3 2021 and has held it in 8 quarters since. The position peaked at $25.7M in Q2 2022. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Pictet Asset Management (Switzerland) held 8,674 shares of CRISPR Therapeutics worth $487K as of Q2 2023.
Pictet Asset Management (Switzerland) left its CRISPR Therapeutics share count unchanged in Q2 2023.
CRISPR Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1255 holding.
Pictet Asset Management (Switzerland) first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s CRISPR Therapeutics position peaked at $25.7M in Q2 2022.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.